Company
Genuity Science (acquired)
Last updated 2026-05-30· 1 min read
Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.
What it was
Genuity Science (formerly WuXi NextCODE Health, formerly NextCODE Health) was an Iceland/Boston-based genomics company that pioneered analysis of population-scale genomic data for drug-target discovery and patient stratification.
It was acquired by HealthVerity in 2023, ending its independent existence.
Why it matters historically
Genuity (and its predecessor deCODE genetics, separately) demonstrated that:
- Population-scale genomic + phenotypic data can identify novel drug-target genes through statistical association.
- Founder populations (Iceland, Finland) provide unique power for rare- variant discovery.
- Genomics + EHR integration accelerates pharmaceutical drug development.
Influence on longevity research
The general approach — large-scale genomic + multi-omic + phenotypic integration to find aging modifiers — is now standard at Calico, BioAge, and many others. Genuity was an early-stage demonstration of the model.
What it is
Genuity Science (formerly Genomics Medicine Ireland, then WuXi NextCODE Ireland) is a population-genomics company operating one of the largest whole-genome-sequencing programmes tied to a national health system. It combines the Irish population's genomic data with clinical phenotypes to power biomarker and drug-target discovery.
Longevity relevance
- Ireland's population has a rich founder-effect signal for identifying rare disease-causing and disease-protective variants.
- The consented cohort enables longitudinal linkage of genomic data with clinical outcomes — useful for aging-biomarker discovery.
- Genuity's pipeline includes both diagnostic and therapeutic-target outputs, with partnerships across major pharma.
The population-genomics category is a slow-burn area: value accrues over many years as cohort size, follow-up, and phenotype depth all compound.